Urinary tract infection in the neurogenic bladder

Area of Science:

• Urology
• Nephrology
• Infectious Diseases

Background:

• Neurogenic bladder (NB) significantly increases the risk of urinary tract infections (UTIs), leading to substantial morbidity and healthcare costs.
• Understanding unique NB-related risk factors (structural, physiological, immunological, catheter-related) is crucial for prevention and management.
• Accurate UTI diagnosis in NB patients is complex and cannot rely on urinalysis or clinical presentation alone.

Purpose of the Study:

• To review and synthesize current knowledge on risk factors, diagnosis, treatment, and prevention of UTIs in neurogenic bladder.
• To provide guidance for healthcare providers on managing UTIs in this vulnerable patient population.

Main Methods:

• Literature review of risk factors, diagnostic criteria, treatment strategies, and preventative measures for UTIs in NB.
• Analysis of current guidelines and evidence for UTI management in neurogenic bladder.
• Synthesis of findings to inform clinical practice and future research directions.

Main Results:

• UTI diagnosis in NB requires a culture with ≥10^3 CFU/mL plus symptoms; urinalysis or clinical signs alone are insufficient.
• Acute UTIs warrant 5-14 day antibiotic treatment based on severity, resistance patterns, and narrow-spectrum selection.
• Asymptomatic bacteriuria (AB) should not be treated due to rising resistance and lack of efficacy.
• Preventative measures include closed catheter drainage and clean intermittent catheterization (CIC); hydrophilic/impregnated catheters are not recommended.
• Emerging strategies like Intravesical Botox, bacterial interference, and sacral neuromodulation show promise for UTI prevention in high-risk NB patients.

Conclusions:

• Comprehensive understanding and modification of risk factors are key to managing UTIs in NB.
• Adherence to specific diagnostic criteria and judicious antibiotic use are essential.
• Preventative strategies, particularly CIC and closed drainage, are vital.
• Further research, including multi-center trials, is needed to validate novel preventative therapies.